ArQule Company Profile (NASDAQ:ARQL)

About ArQule

ArQule logoArQule, Inc. is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focuses on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of over four drug candidates, all of which are in targeted patient populations. The Company's lead product candidate is tivantinib (ARQ 197), an orally administered, small molecule inhibitor of the c-Met receptor tyrosine kinase (MET) and its biological pathway. The Company's product candidates include ARQ 092, designed to inhibit the AKT serine/threonine kinase; ARQ 087, a multi-kinase inhibitor designed to inhibit the fibroblast growth factor receptor (FGFR) family, and ARQ 761, a Beta lapachone analog being evaluated in investigator-sponsored testing as a promoter of NQO1-mediated programmed cancer cell necrosis.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: ARQL
  • CUSIP: 04269E10
Key Metrics:
  • Previous Close: $1.46
  • 50 Day Moving Average: $1.59
  • 200 Day Moving Average: $1.67
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.80
  • P/E Growth: -0.88
  • Market Cap: $103.81M
  • Outstanding Shares: 71,106,000
  • Beta: 1.39
Additional Links:
Companies Related to ArQule:

Analyst Ratings

Consensus Ratings for ArQule (NASDAQ:ARQL) (?)
Ratings Breakdown: 1 Hold Rating, 1 Buy Rating
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $3.75 (158.62% upside)

Analysts' Ratings History for ArQule (NASDAQ:ARQL)
DateFirmActionRatingPrice TargetDetails
3/1/2016Leerink SwannLower Price TargetMarket Perform$3.00 -> $2.50View Rating Details
12/27/2015Royal Bank Of CanadaUpgradeBuyView Rating Details
(Data available from 8/29/2014 forward)


Earnings History for ArQule (NASDAQ:ARQL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/3/2016Q216($0.08)($0.07)$1.13 million$1.07 millionViewN/AView Earnings Details
5/4/2016Q116($0.07)($0.08)$1.63 million$1.28 millionViewN/AView Earnings Details
2/29/2016Q415($0.06)($0.05)$2.40 million$2.80 millionViewListenView Earnings Details
11/4/2015Q315($0.08)($0.04)$2.60 million$2.65 millionViewN/AView Earnings Details
8/5/2015Q215($0.08)($0.06)$2.50 million$3.04 millionViewN/AView Earnings Details
5/6/2015Q115($0.08)($0.07)$1.98 million$2.79 millionViewN/AView Earnings Details
3/4/2015Q414($0.13)($0.06)$1.90 million$3.02 millionViewN/AView Earnings Details
11/10/2014Q314($0.13)($0.10)$2.20 million$2.66 millionViewN/AView Earnings Details
8/5/2014Q214($0.12)($0.10)$2.43 million$2.90 millionViewN/AView Earnings Details
5/7/2014Q114($0.11)($0.11)$2.29 million$2.67 millionViewN/AView Earnings Details
3/5/2014Q413($0.13)($0.10)$2.27 million$2.28 millionViewN/AView Earnings Details
10/31/2013Q313($0.13)($0.10)$2.77 million$3.50 millionViewN/AView Earnings Details
7/30/2013Q2 2013($0.12)($0.11)$3.84 million$4.44 millionViewN/AView Earnings Details
5/8/2013Q1 2013($0.11)($0.09)$3.78 million$5.66 millionViewN/AView Earnings Details
3/14/2013Q4 2012($0.13)($0.09)$5.17 million$5.14 millionViewN/AView Earnings Details
11/1/2012($0.07)($0.01)ViewN/AView Earnings Details
8/2/2012($0.07)($0.01)ViewN/AView Earnings Details
5/3/2012($0.07)($0.08)ViewN/AView Earnings Details
3/1/2012($0.09)$0.07ViewN/AView Earnings Details
11/10/2011($0.23)($0.04)ViewN/AView Earnings Details
8/4/2011($0.19)($0.20)ViewN/AView Earnings Details
5/5/2011($0.08)($0.03)ViewN/AView Earnings Details
3/1/2011($0.15)($0.13)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for ArQule (NASDAQ:ARQL)
Current Year EPS Consensus Estimate: $-0.33 EPS
Next Year EPS Consensus Estimate: $-0.25 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.08)($0.08)($0.08)
Q2 20161($0.08)($0.08)($0.08)
Q3 20161($0.09)($0.09)($0.09)
Q4 20161($0.10)($0.10)($0.10)
(Data provided by Zacks Investment Research)


Dividend History for ArQule (NASDAQ:ARQL)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for ArQule (NASDAQ:ARQL)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/17/2015Michael D LobergDirectorBuy3,719$2.16$8,033.04View SEC Filing  
12/16/2015Michael D LobergDirectorBuy1,231$2.14$2,634.34View SEC Filing  
12/15/2015Paolo PucciCEOBuy1,283$2.16$2,771.28View SEC Filing  
12/11/2015Paolo PucciCEOBuy1,108$2.10$2,326.80View SEC Filing  
12/11/2015Patrick J ZennerDirectorBuy2,300$2.15$4,945.00View SEC Filing  
12/10/2015Paolo PucciCEOBuy7,609$2.10$15,978.90View SEC Filing  
3/11/2015Patrick J ZennerDirectorBuy10,625$2.32$24,650.00View SEC Filing  
11/20/2014Paolo PucciCEOBuy5,000$1.26$6,300.00View SEC Filing  
11/14/2014Patrick J ZennerDirectorBuy20,830$1.20$24,996.00View SEC Filing  
11/13/2014Susan L KelleyDirectorBuy50,000$1.20$60,000.00View SEC Filing  
9/4/2014Paolo PucciCEOBuy5,000$1.31$6,550.00View SEC Filing  
5/23/2014Paolo PucciCEOBuy5,000$1.40$7,000.00View SEC Filing  
5/20/2014Paolo PucciCEOBuy5,000$1.42$7,100.00View SEC Filing  
3/17/2014Patrick ZennerDirectorBuy4,715$2.12$9,995.80View SEC Filing  
3/13/2014Paolo PucciCEOBuy10,000$2.10$21,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for ArQule (NASDAQ:ARQL)
DateHeadline logoETF’s with exposure to ArQule, Inc. : August 25, 2016 (NASDAQ:ARQL) - August 25 at 3:37 PM
News IconPrice Target Update on ArQule, Inc. (NASDAQ:ARQL) - Post News (NASDAQ:ARQL) - August 23 at 7:09 AM
News IconStock Tracking Lower for the Quarter: ArQule Inc. (NASDAQ:ARQL) - Post News (NASDAQ:ARQL) - August 21 at 8:21 AM logoWill ArQule, Inc. (NASDAQ:ARQL) Hit $5 Price Target? - Investor Newswire (NASDAQ:ARQL) - August 19 at 4:12 PM
News IconStock Monitor: PT Update on ArQule, Inc. (NASDAQ:ARQL) - Post News (NASDAQ:ARQL) - August 18 at 11:59 AM
News IconShares Moving Up to a Recent High: ArQule Inc. (NASDAQ:ARQL) - Post News (NASDAQ:ARQL) - August 16 at 3:37 PM
News IconSell-side Spotlight on ArQule, Inc. (NASDAQ:ARQL) - Post News (NASDAQ:ARQL) - August 16 at 3:37 PM logoETF’s with exposure to ArQule, Inc. : August 11, 2016 (NASDAQ:ARQL) - August 11 at 12:50 PM logoARQULE INC Financials (NASDAQ:ARQL) - August 6 at 3:53 PM logoArQule, Inc. :ARQL-US: Earnings Analysis: Q2, 2016 By the Numbers : August 5, 2016 (NASDAQ:ARQL) - August 5 at 3:36 PM logoEdited Transcript of ARQL earnings conference call or presentation 3-Aug-16 1:00pm GMT (NASDAQ:ARQL) - August 3 at 9:15 PM logoEARNINGS SUMMARY: Details of ArQule Inc. Q2 Earnings Report (NASDAQ:ARQL) - August 3 at 12:09 PM logoArQule reports 2Q loss (NASDAQ:ARQL) - August 3 at 12:09 PM
News IconArQule Reports Second Quarter 2016 Financial Results (NASDAQ:ARQL) - August 3 at 12:09 PM logoARQULE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits (NASDAQ:ARQL) - August 3 at 12:09 PM logoCan Shares Of ArQule, Inc. (NASDAQ:ARQL) Hit $5? - Investor Newswire (NASDAQ:ARQL) - July 29 at 3:35 PM
News IconChecking in on Stock Volatility for: ArQule Inc. (NASDAQ:ARQL) - Engelwood Daily (NASDAQ:ARQL) - July 21 at 3:35 PM
News IconWere Analysts Bullish ArQule, Inc. (NASDAQ:ARQL) This Week? - Consumer Eagle (NASDAQ:ARQL) - July 20 at 11:02 PM logoArQule To Report Second Quarter 2016 Financial Results On August 3, 2016 (NASDAQ:ARQL) - July 20 at 7:00 AM logoArQule (ARQL) Announces Presentation of ARQ 531 Preclinical Data - (NASDAQ:ARQL) - July 19 at 3:34 PM
News IconArqule Incorporated (NASDAQ:ARQL) Shorts Decreased by 4.65% After Short Covering - Press Telegraph (NASDAQ:ARQL) - July 19 at 3:34 PM logoArQule Presents Preclinical Data for ARQ 531, a Proprietary Reversible Inhibitor of Wild Type and Mutant BTK, at the 2016 Pan Pacific Lymphoma Conference (NASDAQ:ARQL) - July 18 at 4:00 PM logoStrong Sell Calls For ArQule, Inc. (NASDAQ:ARQL) At 0 - Investor Newswire (NASDAQ:ARQL) - July 15 at 7:51 PM
News IconShares Experiencing a Downtrend: ArQule Inc. (NASDAQ:ARQL) - TGP (NASDAQ:ARQL) - July 15 at 7:51 PM logoArQule, Inc. (ARQL) Updated Price Targets - FTSE News (NASDAQ:ARQL) - July 13 at 3:38 PM
News IconHow Analysts Feel About ArQule, Inc. (NASDAQ:ARQL)? - Consumer Eagle (NASDAQ:ARQL) - July 12 at 9:05 PM
News IconConsensus Target and Stock Rating Report: ArQule, Inc. (NASDAQ:ARQL) - Telanagana Press (NASDAQ:ARQL) - July 12 at 7:17 AM
News IconArqule Incorporated (NASDAQ:ARQL) Sellers Increased By 13.75% Their Shorts - Press Telegraph (NASDAQ:ARQL) - July 9 at 11:38 AM logoIs $5 Within Reach For ArQule, Inc. (NASDAQ:ARQL)? - Investor Newswire (NASDAQ:ARQL) - July 8 at 8:44 PM logoEye Catching Stocks: ArQule Inc. (NASDAQ:ARQL), Dehaier Medical Systems Limited (NASDAQ:DHRM), Lipocine Inc ... - KC Register (NASDAQ:ARQL) - July 8 at 3:35 PM logoBullish Movers: SemiLEDs Corporation (NASDAQ:LEDS), ArQule Inc. (NASDAQ:ARQL), China Commercial Credit, Inc ... - KC Register (NASDAQ:ARQL) - July 8 at 3:35 PM logoArQule, Inc. (ARQL) Current Analyst Ratings - Fiscal Standard (NASDAQ:ARQL) - July 6 at 3:37 PM
News IconShares Dropping Lower in Session: ArQule Inc. (NASDAQ:ARQL) - Telanagana Press (NASDAQ:ARQL) - July 6 at 8:22 AM
News IconShare Volatility in Focus: ArQule Inc. (NASDAQ:ARQL) - Engelwood Daily (NASDAQ:ARQL) - July 5 at 3:32 PM logoArQule to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference on July 12, 2016 (NASDAQ:ARQL) - July 5 at 7:00 AM logoBroker Outlook For The Week Ahead ArQule, Inc. (ARQL) - Fiscal Standard (NASDAQ:ARQL) - July 4 at 3:32 PM
News IconCompany Stock Lower on the Week ArQule Inc. (NASDAQ:ARQL) - Engelwood Daily (NASDAQ:ARQL) - July 2 at 3:36 PM logoNew Broker Ratings For ArQule, Inc. (ARQL) - FTSE News (NASDAQ:ARQL) - July 2 at 3:36 PM logoArQule Presents Preliminary Clinical Data for ARQ 087 Demonstrating Evidence of Anticancer Activity (NASDAQ:ARQL) - July 1 at 8:48 PM logoArQule, Inc. (NASDAQ:ARQL) Expected to Reach Highs Of $5 - Investor Newswire (NASDAQ:ARQL) - July 1 at 3:34 PM logoHere's What The ArQule, Inc. (ARQL) Data Really Means - Insider Monkey (blog) (NASDAQ:ARQL) - July 1 at 3:34 PM
News IconHere’s What The ArQule, Inc. (ARQL) Data Really Means (NASDAQ:ARQL) - July 1 at 12:55 PM logoHere’s What The ArQule, Inc. (NASDAQ:ARQL) Data Really Means (NASDAQ:ARQL) - July 1 at 11:37 AM logoArQule (ARQL) Announces Prelim. Data on ARQ 087 Phase 1/2; Anticancer Activity Observed - (NASDAQ:ARQL) - June 30 at 3:45 PM
News IconUpdate on Stock Volatility for: ArQule Inc. (NASDAQ:ARQL) - Engelwood Daily (NASDAQ:ARQL) - June 30 at 3:45 PM
News IconCheck on Unusual Volume for: ArQule Inc. (NASDAQ:ARQL) - Engelwood Daily (NASDAQ:ARQL) - June 30 at 3:45 PM logoArQule Presents Anti-Cancer Activity For Its ARQ 087 In Rare Liver Cancer (NASDAQ:ARQL) - June 30 at 11:27 AM logoArQule's ARQ 087 shows evidence of anticancer activity in Phase 1/2 study in rare bile duct cancer; shares up 10% premarket (NASDAQ:ARQL) - June 30 at 9:40 AM logoArQule, Inc. (ARQL) Broker Price Targets For The Coming Week - Fiscal Standard (NASDAQ:ARQL) - June 26 at 3:30 PM logoStrong Sell Calls Recommendations For ArQule, Inc. (NASDAQ:ARQL) At 0 - Investor Newswire (NASDAQ:ARQL) - June 25 at 8:54 AM


ArQule (NASDAQ:ARQL) Chart for Monday, August, 29, 2016

Last Updated on 8/29/2016 by Staff